Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.

BioDrugs · 2026 · PMC12790509 · PMID 41247398

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Xeligekimab 200 mg (80.3%) showed a trend towards a higher ASAS20 response rate compared with xeligekimab 100 mg (66.7%) among patients weighing ≥ 70 kg.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.